Page 4 - Immunovant Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunovant, Inc (NASDAQ:IMVT) Given Average Rating of Buy by Analysts

Immunovant, Inc (NASDAQ:IMVT) Given Average Rating of Buy by Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesEva renee barnettPeter salzmannBlackrock incGoldman sachs groupImmunovant incWolfe researchSecurities exchange commissionVanguard group incDeutsche bank aktiengesellschaftGet free reportBank aktiengesellschaftTrading downRenee barnettExchange commissionStreet corp

Immunovant, Inc (NASDAQ:IMVT) Receives $47 88 Consensus Price Target from Brokerages

Immunovant, Inc (NASDAQ:IMVT) Receives $47 88 Consensus Price Target from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Eva renee barnettPeter salzmannPerceptive advisorsHermes incJpmorgan chase coImmunovant incGoldman sachs groupCantor fitzgeraldGet free reportStock downRenee barnettCapital advisorsGet freeImmunovant daily

Immunovant (NASDAQ:IMVT) Given Buy Rating at Truist Financial

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Truist Financial in a report issued on Monday, Benzinga reports. They presently have a $48.00 price target on the stock. Truist Financial’s price target indicates a potential upside of 47.28% from the stock’s previous close. A number of […]

Juliag butchkoPeter salzmannGoldman sachs groupWolfe researchPrincipal financial group incCantor fitzgeraldImmunovant company profileSecurities exchange commissionImmunovant incInvestment company incCitigroup incGet free reportTruist financialExchange commissionFinancial groupHandelsbanken fonder

Immunovant (NASDAQ:IMVT) Stock Rating Reaffirmed by Truist Financial

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Truist Financial in a report issued on Monday, Benzinga reports. They presently have a $48.00 price target on the stock. Truist Financial’s price objective indicates a potential upside of 47.28% from the stock’s previous close. Several other brokerages have […]

United statesPeter salzmannJuliag butchkoDeutsche bank aktiengesellschaftGoldman sachs groupWolfe researchImmunovant company profileBoard of administration florida retirement systemSecurities exchange commissionImmunovant incJpmorgan chase coLife insurance coAlps advisors incHeadlands technologiesGet free reportTruist financial

Fred Alger Management LLC Raises Stock Holdings in Immunovant, Inc (NASDAQ:IMVT)

Fred Alger Management LLC Raises Stock Holdings in Immunovant, Inc (NASDAQ:IMVT)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesEva renee barnettPeter salzmannHoldings channelDeutsche bank aktiengesellschaftSecurities exchange commissionWolfe researchFred alger managementHermes incPerceptive advisorsImmunovant incImmunovant company profileJpmorgan chase coFree reportAlger managementStreet corp